Modus Therapeutics Holding AB (99Z) Price & Analysis

0 Followers

99Z Stock Chart & Stats

€0.03

>-€0.01(-1.57%)

At close: Jan 08 4:00 PM EST

€0.03

>-€0.01(-1.57%)

Day’s Range― - ―

52-Week Range€0.01 - €0.04

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€6.11M

Enterprise Value€39.62

Total Cash (Recent Filing)€12.49M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta2.19

Next Earnings

Nov 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding168,701,800

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero DebtZero debt reduces mandatory interest and repayment obligations, giving Modus greater financial flexibility while it advances its development programs. This conservative leverage profile lowers balance-sheet risk relative to a similarly unprofitable biotech carrying substantial borrowings.

Improved Equity BaseThe materially stronger equity base provides a larger capital cushion for ongoing research and development and indicates that financing has supported the company’s balance sheet. While it does not eliminate funding needs, it improves near-term solvency compared with 2024.

Focused Therapeutic PipelineA clearly defined focus on sickle cell disease and related hematologic conditions gives Modus a concentrated development mandate rather than a broadly dispersed research strategy. Progress in this specialized area could build value around a coherent clinical pipeline over time.

Bears Say

Pre-Revenue ModelThe absence of commercial revenue means Modus currently lacks an operating income stream to fund research, administration, or future clinical work. Its financial progress therefore depends on advancing candidates toward approval, partnering, or other future monetization.

Persistent Operating LossesLarge recurring operating and net losses show that the company has not yet achieved commercial scale or operating leverage. Continued losses can consume shareholder capital and increase the amount of external financing required before the pipeline can generate sustainable earnings.

Heavy Cash BurnSustained negative operating and free cash flow indicates that Modus is not self-funding its development activities. Ongoing burn creates continuing dependence on equity financing or other capital sources, which may constrain execution if funding is not secured.

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.04 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is €6.11M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Nov 24, 2026 which is in 68 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on Aug 26, 2026. The company reported -€0.003 earnings per share for the quarter.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 168,701,800 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -€0.003 in its last earnings report. Following the earnings report the stock price went down -4.545%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in DE:99Z

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.